Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

31. März 2026 15:44 ET | Quelle: Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome

Inhibitor Therapeutics (OTCQB: INTI) updates itraconazole PK study, highlights amorphous formulation and planned global patent filing.
19. März 2026 08:53 ET | Quelle: Sol-Gel Technologies Ltd.

Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025

Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025
17. Dezember 2025 07:00 ET | Quelle: Sol-Gel Technologies Ltd.

Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease

Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease
21. Februar 2023 07:30 ET | Quelle: Palvella Therapeutics

Palvella Therapeutics Announces Pipeline Update on QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ Rapamycin) for Serious, Rare Genetic Skin Diseases with No FDA-approved Therapies

- Pivotal Phase 3 data for the treatment of Pachyonychia Congenita anticipated mid-2023 - - Phase 2 data for the treatment of Microcystic Lymphatic Malformations anticipated March 2023 - - Phase 2b...
28. Mai 2020 16:08 ET | Quelle: Palvella Therapeutics

Palvella Therapeutics Completes $45 Million Series C Financing

Investor Syndicate Comprised of Leading Biotech Investors Proceeds to Accelerate Pipeline of Rare Disease Therapies, Including Late-Stage Programs in Pachyonychia Congenita and Gorlin Syndrome ...